文献速递消化道肿瘤与早癌

TP53是无李-佛美尼相关表型时结直肠癌易感基因

TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes.
PubMed 文献 · Gut · 2020-09-30

该研究在473例家族性/早发性结直肠癌病例中分析TP53,并汇总另外五项研究(总计n=6200),发现TP53致病或可能致病变异在结直肠癌患者中富集(OR=5.7,95%CI 2.8-10.9),且这些患者均不符合TP53检测的临床标准。作者认为TP53致病变异不应与李-佛美尼综合征 unequivocally 关联,需前瞻性随访无LFS表型的携带者以确定监测和管理。

要点

  • TP53致病或可能致病变异在结直肠癌患者中富集,OR=5.7(95%CI 2.8-10.9)。
  • 这些携带者均不符合李-佛美尼综合征的临床检测标准。
  • 功能缺失变异与结直肠癌关联更强(OR=25.44,95%CI 6.10-149.03)。

核心结论

  • TP53致病变异不应与李-佛美尼综合征 unequivocally 关联。
  • 需前瞻性随访无LFS表型的TP53致病变异携带者以确定监测和临床管理方式。

研究设计与样本

  • 分析473例家族性/早发性结直肠癌病例的TP53,并结合另外五项结直肠癌患者研究(总计n=6200)。
  • 对照人群数据来自gnomAD V.2.1.1,LFS数据来自IARC TP53数据库。
  • 所有变异按ACMG/AMP指南及ClinGen TP53专家小组规范重新分类。

主要发现

  • 致病或可能致病变异在对照中占0.05%(n=27/59 095),在结直肠癌患者中占0.26%(n=16/6200)(p<0.0001)(OR=5.7,95%CI 2.8-10.9)。
  • 上述患者均不符合为TP53检测建立的临床标准。
  • 排除诊断年龄>50岁和>60岁的结直肠癌患者后,该关联仍可检测到。
  • 功能缺失和剪接位点等位基因与结直肠癌强关联(OR=25.44,95%CI 6.10-149.03)。
  • 错义致病或可能致病变异与结直肠癌关联(OR=3.58,95%CI 1.46-7.98)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Germline TP53 pathogenic (P) variants cause Li-Fraumeni syndrome (LFS), an aggressive multitumor-predisposing condition. Due to the implementation of multigene panel testing, TP53 variants have been detected in individuals without LFS suspicion, for example, patients with colorectal cancer (CRC). We aimed to decipher whether these findings are the result of detecting the background population prevalence or the aetiological basis of CRC. DESIGN: We analysed TP53 in 473 familial/early-onset CRC cases and evaluated the results together with five additional studies performed in patients with CRC (total n=6200). Control population and LFS data were obtained from Genome Aggregation Database (gnomAD V.2.1.1) and the International Agency for Research on Cancer (IARC) TP53 database, respectively. All variants were reclassified according to the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP), following the ClinGen TP53 Expert Panel specifications. RESULTS: P or likely pathogenic (LP) variants were identified in 0.05% of controls (n=27/59 095) and 0.26% of patients with CRC (n=16/6200) (p<0.0001) (OR=5.7, 95% CI 2.8 to 10.9), none of whom fulfilled the clinical criteria established for TP53 testing. This association was still detected when patients with CRC diagnosed at more advanced ages (>50 and>60 years) were excluded from the analysis to minimise the inclusion of variants caused by clonal haematopoiesis. Loss-of-function and missense variants were strongly associated with CRC as compared with controls (OR=25.44, 95% CI 6.10 to 149.03, for loss of function and splice-site alleles, and OR=3.58, 95% CI 1.46 to 7.98, for missense P or LP variants). CONCLUSION: TP53 P variants should not be unequivocally associated with LFS. Prospective follow-up of carriers of germline TP53 P variants in the absence of LFS phenotypes will define how surveillance and clinical management of these individuals should be performed.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Terradas M, Mur P, Belhadj S, et al. TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut. 2020. PMID: 32998877. doi:10.1136/gutjnl-2020-321825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。